NCT07314983 Long-term Anticoagulation in a Patient With Severe Hemophilia A
| NCT ID | NCT07314983 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Hemophilia A |
| Study Type | OBSERVATIONAL |
| Enrollment | 1 participants |
| Start Date | 2025-09-22 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1 participants in total. It began in 2025-09-22 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII) deficiency of \<1%. Anticoagulation remains a real challenge in these patients, given the precarious hemostatic balance between the bleeding risk associated with anticoagulation and the antithrombotic protection associated with factor VIII deficiency. The advent of new replacement therapies, characterized by FVIII molecules with a prolonged or very prolonged half-life, provides a high level of FVIII coverage (and therefore protection against the risk of bleeding) in patients receiving prophylaxis, thus facilitating the initiation of anticoagulation therapy.
Eligibility Criteria
Inclusion Criteria: * Adult patient (≥ 18 years) with severe hemophilia A * Absence of written objection in the subject's medical record to the reuse of their data for scientific research purposes. Exclusion Criteria: \- Subject having expressed objection to the reuse of their data for scientific research
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07314983 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hemophilia A. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07314983 currently recruiting?
Yes, NCT07314983 is actively recruiting participants. Contact the research team at laurent.sattler@chru-strasbourg.fr for enrollment information.
Where is the NCT07314983 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT07314983 clinical trial?
NCT07314983 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 1 participants.